IO360° Summit

Elliot Norry, MD, FACP, CMO, Adaptimmune LLC

9:10AM - 9:35AM

Keynote: CAR-T in Autoimmune Diseases

Prof. Dr. Georg Schett, VP Research FAU and Head of Department of Medicine 3 – Rheumatology and Immunology, Uniklinikum Erlangen and FAU Erlangen-Nürnberg

9:35AM - 10:10AM

Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies

Moderator:

Sarah Warren, PhD, Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation, Kite Pharma / Gilead Sciences

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies

Rachel Humphrey, MD, President and Founding CEO, Normunity

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Showing Events in 1 Track from 10:10am to 10:50am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

10:10AM - 10:50AM

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 10:50am to 11:50am

Track 1 Grand Ballroom

Track Chair:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

PRAME TCR-Ts: Delivering the Power of T cells to Patients with Solid Cancers

Delfi Krishna, PhD, MBA, Vice President Late-Stage Development, Immatics Biotechnologies

Bispecifics: The Next Generation of CTLA-4 and PD1 Inhibition

John Kurland, PhD, VP, Global Product Leader IO - GI and Head and Neck Cancers, AstraZeneca

Updated Safety and Efficacy Results From Phase 1/2 Study of HPK1 Inhibitor NDI-101150 in Advanced Solid Tumors

David A. Braun, MD, PhD, Louis Goodman and Alfred Gilman Yale Scholar & Assistant Professor of Medicine, Pathology, and Urology, Yale School of Medicine

Track 2 Back Bay Ballroom AB

Track Chair:

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Clinical and Translational Learnings During Development of Abecma - The First Approved Myeloma CAR -T Cell Therapy

Timothy Campbell, MD, PhD, VP, Hematology and Cell Therapy, Early Clinical Development, BMS

CHS-114: A Highly Selective Cytolytic CCR8 Monoclonal Antibody Treatment in HNSCC Patients with and without Toripalimab

Varun Kapoor, PhD, Senior Director, Translational Medicine, Coherus Biosciences

ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance

Peter (Peizhi) Luo, PhD, Chairman, CEO & President of R&D, Adagene

Showing Events in 1 Track from 12:10pm to 01:10pm

Lunch

12:10PM - 1:10PM

Lunch on Own & 1:1 Partnering Meetings

Showing Events in 1 Track from 01:10pm to 02:40pm

IO Clinical Advancements Plenary (Continued) Grand Ballroom

Track Chair:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

1:10PM - 1:30PM

Neoadjuvant Immunotherapy Clinical Developments in Multiple Tumor Types

Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

1:30PM - 2:00PM

Advancing Cancer Vaccines and Neoantigen Therapies: Taking AIM on a New Approach to Outsmart Cancer

Led By:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

Laureen Ojalvo, MD PhD, Executive Medical Director, Oncology Clinical Development, Moderna Therapeutics

Wei Zheng, PhD, Head of Oncology Bioinformatics, Moderna Therapeutics

2:00PM - 2:20PM

Progress Update on TCR-Targeted Bispecific Antibody Monotherapy in Anti-PD(L)1-Resistant Solid Tumors: Phase 1/2 Study Findings

Zhen Su, MD, MBA, CEO & Director, Marengo Therapeutics

2:20PM - 2:40PM

Solid Tumor CD3 Redirectors

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

Showing Events in 1 Track from 02:45pm to 02:50pm

End of Conference

2:45PM - 2:50PM

End of Conference

Showing Events in 1 Track from 08:00am to 10:10am

IO Clinical Advancements Plenary
Grand Ballroom

8:00AM - 8:30AM

Registration & 1:1 Partnering Meetings

8:35AM - 8:45AM

Day Three Welcome

Co-Chairs:

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

8:45AM - 9:10AM

Keynote: Adaptimmune's Pioneering TCR-Based Cell Therapy - Transforming Treatment for Solid Tumors

Elliot Norry, MD, FACP, CMO, Adaptimmune LLC

9:10AM - 9:35AM

Keynote: CAR-T in Autoimmune Diseases

Prof. Dr. Georg Schett, VP Research FAU and Head of Department of Medicine 3 – Rheumatology and Immunology, Uniklinikum Erlangen and FAU Erlangen-Nürnberg

9:35AM - 10:10AM

Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies

Moderator:

Sarah Warren, PhD, Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation, Kite Pharma / Gilead Sciences

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies

Rachel Humphrey, MD, President and Founding CEO, Normunity

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Showing Events in 1 Track from 10:10am to 10:50am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

10:10AM - 10:50AM

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 10:50am to 11:50am

Track 1
Grand Ballroom

Track Chair:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

PRAME TCR-Ts: Delivering the Power of T cells to Patients with Solid Cancers

Delfi Krishna, PhD, MBA, Vice President Late-Stage Development, Immatics Biotechnologies

Bispecifics: The Next Generation of CTLA-4 and PD1 Inhibition

John Kurland, PhD, VP, Global Product Leader IO - GI and Head and Neck Cancers, AstraZeneca

Updated Safety and Efficacy Results From Phase 1/2 Study of HPK1 Inhibitor NDI-101150 in Advanced Solid Tumors

David A. Braun, MD, PhD, Louis Goodman and Alfred Gilman Yale Scholar & Assistant Professor of Medicine, Pathology, and Urology, Yale School of Medicine

Track 2
Back Bay Ballroom AB

Track Chair:

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Clinical and Translational Learnings During Development of Abecma - The First Approved Myeloma CAR -T Cell Therapy

Timothy Campbell, MD, PhD, VP, Hematology and Cell Therapy, Early Clinical Development, BMS

CHS-114: A Highly Selective Cytolytic CCR8 Monoclonal Antibody Treatment in HNSCC Patients with and without Toripalimab

Varun Kapoor, PhD, Senior Director, Translational Medicine, Coherus Biosciences

ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance

Peter (Peizhi) Luo, PhD, Chairman, CEO & President of R&D, Adagene

Showing Events in 1 Track from 12:10pm to 01:10pm

Lunch

12:10PM - 1:10PM

Lunch on Own & 1:1 Partnering Meetings

Showing Events in 1 Track from 01:10pm to 02:40pm

IO Clinical Advancements Plenary (Continued)
Grand Ballroom

Track Chair:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

1:10PM - 1:30PM

Neoadjuvant Immunotherapy Clinical Developments in Multiple Tumor Types

Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

1:30PM - 2:00PM

Advancing Cancer Vaccines and Neoantigen Therapies: Taking AIM on a New Approach to Outsmart Cancer

Led By:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

Laureen Ojalvo, MD PhD, Executive Medical Director, Oncology Clinical Development, Moderna Therapeutics

Wei Zheng, PhD, Head of Oncology Bioinformatics, Moderna Therapeutics

2:00PM - 2:20PM

Progress Update on TCR-Targeted Bispecific Antibody Monotherapy in Anti-PD(L)1-Resistant Solid Tumors: Phase 1/2 Study Findings

Zhen Su, MD, MBA, CEO & Director, Marengo Therapeutics

2:20PM - 2:40PM

Solid Tumor CD3 Redirectors